SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Indications -- Hepatitis
An SI Board Since March 2001
Posts SubjectMarks Bans
312 28 0
Emcee:  tuck Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
287Looks like an even match, IMO. Good situation for third-party payers and ex-US gDewDiligence_on_SI-7/28/2017
286So, Vosevi still have slight/small advantage over Maviret. But, as I mentioned oMiljenko Zuanic-7/28/2017
285European Commission approves GILD’s Vosevi and ABBV/ENTA’s Maviret, direct compeDewDiligence_on_SI-7/28/2017
284ABBV/ENTA’s G/P receives early-access approval in UK for hard-to-treat patients:DewDiligence_on_SI-5/11/2017
283JNJ/ACHN's 3-DAA regimen has a problem: siliconinvestor.comDewDiligence_on_SI-4/22/2017
282MRK’s 3-DAA HCV regimen fails to impress (IMO): siliconinvestor.comDewDiligence_on_SI-11/13/2016
281HCV DAAs can reactivate (latent) HBV, says FDA: fda.govDewDiligence_on_SI-10/4/2016
280C&EN NASH article: cen.acs.org ENTA-related excerpts from same article: silDewDiligence_on_SI-10/3/2016
279FDA approves MRK’s HCV combo with recommended RAV screening for GT1a patients: DewDiligence_on_SI-1/28/2016
278BMY plans to test anti-PD-L1 drug in HBV. (Source: BofA webcast.)DewDiligence_on_SI-5/12/2015
277FDA approves ABBV/ENTA 3-DAA regimen called Viekira Pak: fda.govDewDiligence_on_SI-12/19/2014
276‘Cheat Sheet’ for GILD’s phase-3 trials of Sovaldi+GS-5816: siliconinvestor.comDewDiligence_on_SI-7/28/2014
275Triaging of HCV patients (from today’s Boston Globe): siliconinvestor.comDewDiligence_on_SI-6/1/2014
274The CDC and HHS are helping to get the word out about the dangers of untreated HDewDiligence_on_SI-4/23/2014
273Phase-3 HCV Datasets for ABBV/ENTA vs GILD (you be the judge): siliconinvestorDewDiligence_on_SI-2/2/2014
272‘Cheat Sheet’ for BMY’s phase-3 trials of Sovaldi + Daclatasvir: siliconinvestorDewDiligence_on_SI-1/12/2014
271Musings on GILD's excellent 'ION' data: siliconinvestor.comDewDiligence_on_SI-12/18/2013
270GILD borrows a page from ABBV/ ENTA in HCV: siliconinvestor.comDewDiligence_on_SI-11/14/2013
269GILD's executive officers continue their colossal insider selling: siliconinDewDiligence_on_SI-11/9/2013
268GILD starts "GT3 bailout" trial: siliconinvestor.comDewDiligence_on_SI-10/16/2013
267Cheat Sheet for ABBV/ENTA Phase-3 HCV Program (expanded & updated): siliconDewDiligence_on_SI-9/16/2013
266Demystifying ABBV/ENTA’s SAPHIRE-1/2 trials: siliconinvestor.comDewDiligence_on_SI-9/5/2013
265Cheat Sheet for ABBV/ENTA Phase-3 HCV Program: siliconinvestor.com DewDiligence_on_SI-7/28/2013
264Please vote in new iHub survey on competition for hegemony in all-oral HCV: siliDewDiligence_on_SI-11/13/2012
263ABT is running *7* phase-3 trials in genotype-1 HCV: siliconinvestor.com silicoDewDiligence_on_SI-11/12/2012
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News